A position paper recently published by the National Pulmonary Embolism Response Team outlines an approach for diagnosing and treating pulmonary embolism in patients with COVID-19.
The surgical management of patients with massive pulmonary embolism and high-risk submassive PE was found to be safe and highly effective for achieving right ventricular recovery.
A combination of C-arm computed tomography with conventional digital subtraction angiography of the pulmonary arteries can enhance the diagnostic work-up of patients with suspected CTEPH.
The placement of an inferior vena cava filter reduced the rate of pulmonary embolism in patients with deep venous thrombosis and cancer.
The odds of developing pulmonary embolism were lower in patients taking statin therapy prior to admission.
All hospitalized patients with COVID-19 should be started on prophylactic low-molecular-weight heparin.
The researchers found that 30 percent of the patients with COVID-19 had positive findings for acute pulmonary emboluson pulmonary CT angiogram; the remaining patients had negative findings on CT.
An RV/LV ratio >1.0 was not associated with fewer favorable outcomes in patients with symptomatic acute pulmonary embolism who were otherwise considered otherwise low risk.
In patients with acute pulmonary embolism, surgical embolectomy demonstrated survival improvements.
The FDA has approved the first generics of Eliquis tablets.
